RANKL Inhibition and Mammographic Breast Density

Official Title

Randomized Clinical Trial of RANKL Inhibition with Denosumab on Mammographic Density in High Risk Premenopausal Women with Dense Breasts

Study Details

Researchers at Washington University School of Medicine and physicians at Siteman Cancer Center are carrying out a study to determine whether a drug called denosumab (currently in use to prevent fractures and treat osteoporosis) can reduce breast density in women who have dense breasts. This study could help identify novel ways to prevent breast cancer in younger women.

Principal Investigator

Dr. Adetunji Toriola

IRB Number



1. Participants must be female and at least 40 years of age
2. Participants must be premenopausal
3. Participants must have dense breasts on routine mammogram

Volunteer Information

For more information about this study, contact Volunteer for Health at: